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Adverse drug reactions associated with
amitriptyline — protocol for a systematic
multiple-indication review and meta-
analysis
Maria-Sophie Brueckle1* , Elizabeth T. Thomas2, Svenja E. Seide3, Maximilian Pilz3, Ana Isabel Gonzalez-Gonzalez1,
Truc Sophia Nguyen1, Sebastian Harder4, Paul P. Glasziou2, Ferdinand M. Gerlach1 and Christiane Muth1
Abstract
Background: Unwanted anticholinergic effects are both underestimated and frequently overlooked. Failure to
identify adverse drug reactions (ADRs) can lead to prescribing cascades and the unnecessary use of over-the-
counter products. The objective of this systematic review and meta-analysis is to explore and quantify the
frequency and severity of ADRs associated with amitriptyline vs. placebo in randomized controlled trials (RCTs)
involving adults with any indication, as well as healthy individuals.
Methods: A systematic search in six electronic databases, forward/backward searches, manual searches, and
searches for Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval studies, will be
performed. Placebo-controlled RCTs evaluating amitriptyline in any dosage, regardless of indication and without
restrictions on the time and language of publication, will be included, as will healthy individuals. Studies of topical
amitriptyline, combination therapies, or including < 100 participants, will be excluded. Two investigators will screen
the studies independently, assess methodological quality, and extract data on design, population, intervention, and
outcomes ((non-)anticholinergic ADRs, e.g., symptoms, test results, and adverse drug events (ADEs) such as falls).
The primary outcome will be the frequency of anticholinergic ADRs as a binary outcome (absolute number of
patients with/without anticholinergic ADRs) in amitriptyline vs. placebo groups. Anticholinergic ADRs will be
defined by an experienced clinical pharmacologist, based on literature and data from Martindale: The Complete Drug
Reference. Secondary outcomes will be frequency and severity of (non-)anticholinergic ADRs and ADEs. The
information will be synthesized in meta-analyses and narratives. We intend to assess heterogeneity using meta-
regression (for indication, outcome, and time points) and I2 statistics. Binary outcomes will be expressed as odds
ratios, and continuous outcomes as standardized mean differences. Effect measures will be provided using 95%
confidence intervals. We plan sensitivity analyses to assess methodological quality, outcome reporting etc., and
subgroup analyses on age, dosage, and duration of treatment.
Discussion: We will quantify the frequency of anticholinergic and other ADRs/ADEs in adults taking amitriptyline
for any indication by comparing rates for amitriptyline vs. placebo, hence, preventing bias from disease symptoms
and nocebo effects. As no standardized instrument exists to measure it, our overall estimate of anticholinergic ADRs
may have limitations.
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Background
About 50 million Europeans live with multimorbidity and
the number is likely to continue rising [1]. Hence, general
practitioners and many patients have to deal with the chal-
lenges of multimorbidity, and the multimedication that is
frequently associated with it, on a daily basis [2]. Multi-
morbidity and multimedication are therefore a research
priority in health care. The risk of drug-drug interactions
in individual patients increases with the number of co-
existing diseases and the number of (prescribed) medicines
taken [3]. Depending on the individual patient’s conditions
and on interactions between drugs and diseases, multime-
dication increases the risk of unwanted outcomes and ser-
ious harm [4]. It has been recommended that a distinction
should be made between adverse drug reactions (ADRs)
and adverse drug events (ADEs) [5]. ADRs are defined as
“an appreciable harmful or unpleasant reaction, resulting
from an intervention related to the use of a medicinal
product; ADRs usually predict hazard from future admin-
istration and warrant prevention, or specific treatment, or
alteration of the dosage regimen, or withdrawal of the
product” [6]. ADEs are defined as “a potentially harmful
effect resulting from an intervention related to the use of a
medicinal product, which constitutes a hazard and may or
may not be associated with a clinically appreciable adverse
reaction and/or an abnormal laboratory test or clinical in-
vestigation, as a marker of an adverse reaction.” [5].
In the general population, the prescription of medi-
cinal products with anticholinergic properties has risen
by about 40% over the last 10 years [7]. Older age is
known to increase the likelihood of being prescribed
anticholinergic medicinal products because they are used
to alleviate symptoms that often occur in later life, such
as urinary incontinence, and sleep disorders [8]. As mul-
timedication tends to increase anticholinergic burden in
the elderly, the risk of ADRs is particularly high in medi-
cinal products with anticholinergic effects. This is par-
ticularly true when a medicinal product with strong
anticholinergic properties like amitriptyline is used, or
when anticholinergic burden accumulates due to mul-
tiple prescriptions [9]. Another risk factor for anticholin-
ergic prescriptions is institutionalization [10].
In 1961, amitriptyline was introduced to the US mar-
ket as a tricyclic antidepressant (TCA), and it is still pre-
scribed regularly for major depression [11]. It has been
approved in more than 56 countries worldwide and is
sold under the brand names Saroten, Elavil, and Endep,
among many others [12]. In 2008, it was the third most
frequently prescribed antidepressant in Germany, at 94
million defined daily doses (DDD) [13]. In addition to
major depressive disorder, amitriptyline is used to treat
other forms of depression, chronic pain, migraine, anx-
iety disorders [11], fibromyalgia [14], neuropathic pain
[15], interstitial cystitis [16], nocturnal enuresis [17], eat-
ing disorders, and post-herpetic neuralgia [18].
Amitriptyline inhibits the reuptake of the neurotrans-
mitters serotonin and norepinephrine into the presynaptic
neuron by blocking their noradrenaline and serotonin
transporters [19]. It also has an affinity for the muscarinic,
histaminergic, and adrenergic systems. This affinity is con-
sidered significant for most of the effects of amitriptyline
[19]. Nicotinic anticholinergic receptors (nAChR) are
made up of 5 out of 17 subunits [20]. These receptors
occur mostly on the cells of skeletal muscles, autonomous
ganglia, and the CNS, and control neuromuscular trans-
mission. Muscarinic anticholinergic receptors (mAChR)
are divided into the subtypes M1-M5 and are mostly lo-
cated in the central nervous system (CNS), heart, gastric
tract, genitourinary tract, and respiratory tract. They con-
trol neuronal excitement, memory, learning, heart rate,
analgesia, and extrapyramidal motor activity. Broadly
speaking, ACh effects can be divided into periphery func-
tions (control of skeletal muscles, autonomous nervous
system, parasympathetic, enteral nervous system), and
functions in the CNS (sleep-awake-rhythm, regulation,
impulsion, vigilance, learning, memory) [20].
Commonly observed ADRs when taking anticholinergic
medicines such as amitriptyline are constipation, dry
mouth, dry eyes, tachycardia, urinary retention, agitation,
confusion, delirium, falls, hallucinations, and cognitive
dysfunction [21]. The following ADRs have been specific-
ally reported for amitriptyline: vision problems, dizziness,
sedation, sleepiness, somnolence, drowsiness, tremor, gas-
tralgia, increased appetite, fatigue, asthenia, slow down,
and sexual dysfunction. However, not all of these symp-
toms are caused by muscarinergic inhibition alone [11].
Anticholinergic ADRs are both underestimated and
frequently overlooked in clinical management [21, 22].
Even though they are common, they are often regarded
as “unavoidable” and as part of the aging process or dis-
ease course [23]. Failure to identify ADRs can lead to
“prescribing cascades” [24, 25].This may result in the
prescription of another medicinal product by the phys-
ician, or the increased use of over-the-counter products
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(OTC), rather than the discontinuation or dose adjust-
ment of the responsible medicinal products [26]. With
advancing age, an impeded ability to metabolize drugs
increases the risk of impairment from anticholinergic
burden [27, 28]. There is growing evidence to suggest
that medicines with anticholinergic properties, such as
amitriptyline, may cause serious physical and cognitive
impairment in the elderly population [29]. Current re-
search into amitriptyline concentrates mostly on its ben-
efits and harms in relation to a single indication (e.g.,
depression [11]). We, in contrast, aim to investigate
ADRs to amitriptyline across all indications. The object-
ive of this systematic review and meta-analysis is thus to
explore and quantify the frequency and severity of ADRs
to amitriptyline vs. placebo in randomized controlled tri-
als (RCTs) of adult humans across all indications, as well
as in healthy individuals.
Methods
This systematic review and meta-analysis will be con-
ducted in accordance with the PRISMA statement [30].
Aims
1. To assess ADRs caused by amitriptyline compared
with placebo across indications, and in healthy
subjects
2. To quantify their frequency
3. To quantify their severity
4. To quantify anticholinergic ADRs
5. To assess ADEs caused by amitriptyline compared
with placebo across indications, and in healthy
subjects
6. To identify factors that influence the frequency of
ADRs and ADEs (e.g., age (mean per trial), dose,
gender (proportion per trial), indication)
7. To examine the way ADRs and ADEs are described
in the RCT under review (e.g., reporting individual
reactions vs. reporting one overall number, active
vs. passive assessment, subjective vs. objective
assessment).
Search strategy
We systematically searched multiple electronic databases
including MEDLINE, Embase, PsycINFO, PsycLIT, Psy-
ndex, and the Cochrane Central Register of Controlled
Trials (CENTRAL) from inception. We combined free
text searches with controlled terms such as Placebo
AND (Amitriptyline OR Amitriptylines OR Amineurin
OR Amitrip OR Amitriptylin OR Amitrol OR Anapsique
OR Damilen OR Domical OR Elavil OR Endep) AND
Randomized controlled trials (for the complete search
strategy see Additional file 1).
We will perform citation analysis (forward and back-
ward citation searches) on the studies included in Web
of Science (including SCI - Science Citation Index Ex-
panded, BIOSIS Citation Index, BIOSIS Previews,
Current Contents Connect, Medline), and hand search
the reference lists of systematic reviews. Furthermore,
we will search the Food and Drug Administration (FDA)
and the European Medicines Agency (EMA) databases
for unpublished approval studies. Additionally, we will
ask the major manufacturers of amitriptyline and other
experts for information on further relevant RCTs.
We will search the clinical trial registries ClinicalTrials.gov,
the International Standard Randomized Controlled Trial
Number Register (ISRCTN), and the WHO International
Clinical Trials Registry Platform (ICTRP) for unpublished
studies.
Study selection
Titles and abstracts of retrieved studies will be entered
into Covidence© and independently screened for eligibil-
ity by two reviewers (MSB, ETT). Inclusion and exclu-
sion criteria are provided in Table 1.
Full texts will be obtained for all potentially eligible
studies. The two reviewers will then independently de-
termine eligibility based on inclusion and exclusion cri-
teria. Previous to the assessment, a native speaker will
translate full texts that are only available in languages
other than English or German. Kappa statistics will be
calculated to evaluate inter-observer agreement. Any dis-
agreement over eligibility will be resolved through dis-
cussion with a third reviewer (CM). The detailed
selection process will be shown in a PRISMA flow chart
in the full review.
Appraisal of methodological quality
The two review authors (MSB, ETT) will use the risk of
bias (RoB) tool provided by Cochrane [32] to independ-
ently evaluate the risk of bias in eligible studies. Charac-
teristics will be tabulated, and any disagreement between
the two reviewers will be resolved by discussion with a
third (CM and/or SES). The results of the RoB evalu-
ation will be used in a sensitivity analysis.
Data extraction
In order to carry out a pilot calibration exercise, we
have selected 20 studies from a subsample of 40 stud-
ies included in the Cochrane Review “Amitriptyline
versus placebo for major depressive disorder” [11].
We will develop and calibrate a standardized, elec-
tronic data extraction sheet and manual on the basis
of the following data:
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 Study metadata: authors, year, title, language,
funding, country, setting, and objective (indication
(Table 2), disease or symptom under review)
 Study design: type of randomization (e.g., individual
or cluster-randomized), number of study arms,
crossover, washout, type of blinding (single or
double blinded)
 Population: age (mean per trial), gender (proportion
per trial), sample size, baseline characteristics
(including comorbidity and multimorbidity),
completion rates
 Intervention: dose, frequency of dose delivery, days
of treatment, and mode of application of
amitriptyline, personalized dosage forms (e.g.,
maximum dosage), titration, intervention adherence,
and concomitant medication
 Comparator: passive placebo
 Outcomes: type of ADR (e.g., anticholinergic
symptoms (Table 3)) and other ADRs not
commonly considered to be anticholinergic
(Table 4), outcome reported subjectively (e.g.,
assessment scale) or measured objectively (e.g.,
measurement of salivation), type of data collection
(e.g., systematically assessed or sporadically
reported), time of measurement, length of follow-up,
frequency of ADRs (number or proportion of sub-
jects who have experienced an ADR), severity (e.g.,
mean, standard deviation) of ADRs, type and num-
ber of any reported ADEs (e.g., falls, fall-related frac-
tures, deaths)
To ensure data extraction is reliable, one reviewer
will extract the data (MSB), and another will verify it
(ETT). As we do not expect authors of studies pub-
lished more than 10 years ago to respond to inquiries,
we will only contact authors of studies published in
2009 or later in case of missing data, and then only
when contact details (e-mail address) are provided in
the publication. As research has shown that about
30% of trial authors are unreachable and 40% or
more do not respond to emails, even after several re-
minders [34], we have decided that if no reply is
forthcoming, or the message cannot be delivered, we
will not try to contact the author again. The analysis
will also include available data for studies published
in 2008 or earlier.
Outcomes
The primary outcome will be the frequency of anti-
cholinergic ADRs as a binary outcome (absolute number
of patients with/without any anticholinergic ADRs) in
amitriptyline vs. placebo groups. For this purpose, we
will separately retrieve the absolute number of anti-
cholinergic ADRs (Table 3) for each type of reaction and
for both treatment groups.
We generated the classification scheme by extracting
ADRs in concern to the general population from
Table 1 Inclusion and exclusion criteria for study selection
PICOS
framework
Inclusion criteria Exclusion criteria
Population Adult humans, age ≥ 18 any ethnicity, any sex, any indication, or healthy Not applicable
Intervention Amitriptyline monotherapy: any dose, frequency, duration, and oral mode of
administration (tablets, capsules or liquid form)
Amitriptyline in combination with another
active therapy, topical use of amitriptyline
Comparator Passive placebo (an inert substance that may mimic the ADRs of amitriptyline, i.e.,
nocebo effects).
Comparing amitriptyline with active drugs or
other forms of therapy
Outcome Quantification of ADRs for each group, e.g., absolute numbers (frequency and
severity (mean/sd)), associated with amitriptyline (i.e., negative effects):
(a) caused by its anticholinergic properties and negative effects
(b) not caused by anticholinergic properties
No outcomes relating to adverse drug reactions.
Study
design
Randomized, double-blind, placebo-controlled trials (RCTs) with ≥ 100 subjects in
total for the amitriptyline and placebo arm at baseline: no limitation on publication
date, language, setting, time of follow up. Only the first period of crossover trials will
be extracted (to avoid carry-over effects [31]. We will include trials with more than
two arms, as long as we can identify an amitriptyline and a placebo arm.
Any other study design
Type of
publication
Full publication Abstract, conference presentation, provisional
papers without complete results
Table 2 Indications for amitriptyline
System Indication
Pain
Psychiatry Depression, anxiety disorder, bulimia nervosa
Neurology Depression with headache, headache, prophylaxis of
migraine, prophylaxis of chronic tension-type head-
ache, neuropathic pain, narcolepsy, pathological cry-
ing or laughing
Gastroenterology Irritable bowel syndrome, interstitial cystitis
Rheumatology Fibromyalgia
Toxicology Medication-overuse headache, ciguatera poisoning
Source of data: Martindale: The Complete Drug Reference [33]
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Martindale: The Complete Drug Reference [33]and sup-
plemented them with further reactions that are typical
of an older population by using Collamati et al. [29].
The resulting list contained 39 items. In order to
prioritize the symptoms on the list, an experienced
clinical pharmacologist (SH) first rated them for specifi-
city with regard to anticholinergic ADRs by differentiat-
ing between symptoms that are unequivocally caused
by the inhibition of muscarinergic signaling [35, 36],
and those that are not. Amitriptyline can also cause po-
tassium channel blockades [37], peripheral alpha block-
ades [38], norepinephrine reuptake blockades [39], and
inhibit histamine receptors [40], and sodium channels
[41], all of which potentially cloud the clinical presenta-
tion of anticholinergic ADRs. The items on the list also
needed to be distinguished from intoxication [42, 43].
Subsequently, a list of symptoms was drawn up, which
then became the anticholinergic ADRs under study.
The list consists of 26 ADRs in six organ systems.
ADRs that were deemed to be sufficiently similar were
pooled in groups of aggregated ADRs, such as vision-
related symptoms (see Table 3).
Should the reported ADRs not allow the overall propor-
tion of patients with/without anticholinergic symptoms to
be calculated (e.g., when several symptoms occur in one
patient, and ADRs are reported for each symptom), we
will select the anticholinergic symptom that is most com-
monly reported. For example, if dry mouth is reported as
the most frequent ADR in most of the studies, it will be
selected as the primary outcome. Secondary outcomes will
be the frequency and severity of any pre-specified anti-
cholinergic and non-anticholinergic ADRs (Table 3 and
Table 4). Additionally, we will look for any other ADRs
and ADEs (e.g., falls and deaths) that are reported in the
studies. For this purpose, we will separately retrieve the
absolute number of ADRs/ADEs, as well as the group
sizes, for each reaction and for both treatment groups. We
will then classify the reactions according to the classifica-
tion provided in Table 3 and Table 4.
Data synthesis
Firstly, we will describe the data trial wise in terms of
study characteristics such as study design, participants,
dosing, harms detection, and others. Secondly, we will use
forest plots to graphically display the frequency, nature,
and severity of the ADRs, along with their confidence in-
tervals, for each trial. We will provide a quantitative syn-
thesis of findings from the included studies using the
random-effects model with inverse variance weighting and
Table 3 Anticholinergic (antimuscarinic) adverse drug reactions to amitriptyline
System Aggregated variables Symptom
Gastrointestinal tract as Dry mouth-related symptoms Dry mouth, difficulty chewing, difficulty swallowing, difficulty speaking
Digestion-related symptoms Constipation
Genitourinary tract Genitourinary-related symptoms Urinary retention
Eye and adnexa Vision-related symptoms Blurred vision, disturbances in accommodation, and adaptation
Skin Thermoregulation related symptoms Hot dry skin, hyperthermia, anidrosis
Cardiovascular system Cardiovascular-related symptoms Tachycardia, palpitations, tachyarrhythmia
Nervous system 1. Fatigue-related symptoms Fatigue
2. Attention-related symptoms Inability to concentrate, confusion, disorientation
3. Memory-related symptoms Mild amnesia, memory impairment
4. Restlessness-related symptoms Excitement, restlessness, agitation
5. Coordination-related symptoms Ataxia, hyperreflexia
Source of data: Martindale: The Complete Drug Reference [33], Collamati et al. 2016 [29]
Table 4 Non-anticholinergic adverse drug reactions to
amitriptyline
System Symptom
Gastrointestinal
tract
Sour or metallic taste
Stomatitis
Gastric irritation
Nausea and vomiting
Hypersensitivity
reactions
Urticaria
Angioedema
Photosensitization
Cholestatic jaundice
Blood disorders such as eosinophilia
Bone-marrow depression
Thrombocytopenia
Leucopenia
Agranulocytosis
Endocrine system Testicular enlargement
Gynecomastia
Breast enlargement
Galactorrhoea
Sexual dysfunction
Changes in blood sugar concentrations
Hyponatremia associated with inappropriate
secretion of antidiuretic hormone
Other adverse
effects
Increased appetite with weight gain (or occasional
anorexia with weight loss)
Sweating
Source of data: Martindale: The Complete Drug Reference [33]
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the DerSimonian-Laird estimator to assess between-trial
heterogeneity [44]. For each study, we will provide sum-
maries of intervention effects by calculating odds ratios
(OR) for dichotomous outcomes (such as the ADRs) and
standardized mean differences for continuous outcomes
(such as the severity of ADRs), along with their 95% confi-
dence intervals. We do not expect to be able to measure
time-to-event outcomes.
In order to assess publication bias, we will separately
use funnel plots and the Egger regression test [45] for
each outcome.
We expect the number of eligible studies to be high
enough to permit us to perform a meta-analysis. How-
ever, as we expect trials to report a range of different
outcome measures, we will assess comparability before
conducting a quantitative synthesis.
Statistics
Between-trial heterogeneity will be assessed by interpreting
its magnitude relative to the scale on which the combined
effect is reported, and by calculating the I2 statistic. When
studies are sufficiently homogeneous, we will pool the re-
sults using a random-effects meta-analysis with standard-
ized mean differences for continuous outcomes and odds
ratios for binary outcomes, and we will calculate 95% con-
fidence intervals and 2-sided p values for each outcome.
We will use the DerSimonian-Laird estimator to assess
between-trial heterogeneity [44]. Whenever more than five
studies are included in the meta-analysis and the outcomes
are binary, confidence intervals will be adjusted using the
methods proposed by Hartung and Knapp [46–50]. Meta-
regression will be used to explain heterogeneity at different
time points, and for each indication and mode of adminis-
tration. We will conduct sensitivity analyses based on
study quality and the type of outcome reporting (objective
vs. patient reported). We will use forest plots to illustrate
the meta-analysis graphically, and will assess evidence of
publication bias by means of funnel plots, and by assessing
the skewness of the standardized deviates [51]. All analyses
will be performed in R version 3.6.1 or higher [52].
Planned sensitivity and subgroup analyses
We will test the robustness of our results in sensitivity
analyses that take into account the risk of bias as well as
parameters of reporting quality.
For the subgroup analysis, we will look at mean age
per trial. Provided enough studies are available, we will
set the cutoff to ≥ 65 years for older/younger adults and
≥ 80 years for very old vs. younger and older adults. We
will additionally perform subgroup analyses based on the
proportion of males per trial, average duration of the
treatment (≤ 1 week, ≥ 1 week, ≥ 4 weeks), average dosage
(< 50mg, 50–99 mg, 100–150 mg, > 150 mg), and indica-
tion. Assuming it is possible, we will also base the
analyses on the proportion of frail patients per trial, pro-
portion of disabled patients per trial and multimorbidity
(≥ 3 diseases on average per trial vs. < 3 diseases on aver-
age per trial).
Discussion
The results of this review will quantify the frequency of
anticholinergic ADRs in adults taking amitriptyline com-
pared with placebo for all indications and provide infor-
mation on the most common adverse drug reactions and
associated symptom patterns. Current evidence on anti-
cholinergic effects is often based on observational data
(e.g., [53, 54]), which may be biased, as they cannot distin-
guish anticholinergic symptoms from disease symptoms
and nocebo effects [55]. In the meta-analysis of Ruxton
et al. that studied the anticholinergic side effects of antide-
pressants in a total 124,286 participants, data were derived
mostly from prospective or retrospective cohorts [54].
A major strength of our multiple-indication review of
randomized placebo controlled trials is the design of our
study. The first of these is the restriction to the studies
with placebo group controls for disease-related symp-
toms and nocebo effects. Secondly, including studies of
all conditions increase the power to detect rare ADRs,
and small but important increases in common symp-
toms. RCTs are usually underpowered and the unin-
tended effects are expected to be the same, regardless of
the indication for the intervention [56–60]. Thirdly, our
review avoids the problem of “overlapping” when a
multiple-indication review consists of systematic reviews
that include some, but not all, of the same studies [56].
A limitation is the clinical heterogeneity and specifically
the potential interaction with the type of condition. We
therefore pre-specified condition subgroups for analysis.
A major limitation is also that a single expert drew up
the list of pre-specified anticholinergic ADRs rather than
a group of interdisciplinary experts. Some subjectivity in
the selection of symptoms summarized in our primary
outcome, anticholinergic ADRs, is therefore possible. A
further limitation is the restriction to RCTs with a sam-
ple size of 100 or more study participants. This will de-
crease the power of our analyses and limit our ability to
detect rare events [57]. On the other hand, the combin-
ation of very small-scale studies with RCTs involving
many participants would increase the heterogeneity be-
tween trials [56]. Other sources of heterogeneity, such as
age of participants, indication, dose, duration of treat-
ment, and methodological quality of studies, will be ana-
lyzed carefully. Another potential limitation is that our
search and selection process may miss relevant studies.
As this is the first systematic review of randomized con-
trolled trials of anticholinergic ADRs of amitriptyline
across multiple indications, no direct comparison with
existing literature is possible. However, we identified
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systematic reviews on amitriptyline that focused on single
indications and included an assessment of harms [11, 14,
15, 61]. We will be able to compare our results with those
published in these reviews, as some of our pre-specified
ADRs overlap.
The results of our multiple-indication review will sup-
port clinical decision-making in adult patients and help
physicians decide whether the expected benefits of ami-
triptyline will outweigh potential harms arising from
anticholinergic ADRs.
Supplementary information
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1186/s13643-020-01296-8.
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